Bibliografía recomendada

Publicaciones sobre Prescripción de Heroína y otros opióides

Treatment of opiate dependence in hands of primary care providers. Public Health Rep 2003; 118(1):76.

Adrian M. Whose needs are to be met? Customer satisfaction with delivery of treatment services for heroin users. Subst Use Misuse 2002; 37(4):543-7.

Andre P, Gremy F, Fourcade J, Bruere-Dawson C, Bonnin M, Herve C. [Representations, discourses and practices about drug substitution with opiates. Apropos of a survey conducted in cooperation with 97 French physicians]. Ann Med Interne (Paris) 1996; 147(1):20-30.

Aszalos R, McDuff DR, Weintraub E, Montoya I, Schwartz R. Engaging hospitalized heroin-dependent patients into substance abuse treatment. J Subst Abuse Treat 1999; 17(1-2):149-58.

Backmund M, Meyer K, Eichenlaub D, Schutz CG. Predictors for completing an inpatient detoxification program among intravenous heroin users, methadone substituted and codeine substituted patients. Drug Alcohol Depend 2001; 64(2):173-80.

Bammer G, Dobler-Mikola A, Fleming PM, Strang J, Uchtenhagen A. The heroin prescribing debate: integrating science and politics. Science 1999; 284(5418):1277-8.

Banys P, Clark HW, Tusel DJ et al. An open trial of low dose buprenorphine in treating methadone withdrawal. J Subst Abuse Treat 1994; 11(1):9-15.

Bartu A, Freeman NC, Gawthorne GS, Allsop SJ, Quigley AJ. Characteristics, retention and readmissions of opiod-dependent clients treated with oral naltrexone. Drug Alcohol Rev 2002; 21(4):335-40.

Bell J, Dru A, Fischer B, Levit S, Sarfraz MA. Substitution therapy for heroin addiction. Subst Use Misuse 2002; 37(8-10):1149-78.

Blattler R, Dobler-Mikola A, Steffen T, Uchtenhagen A. Decreasing intravenous cocaine use in opiate users treated with prescribed heroin. Soz Praventivmed 2002; 47(1):24-32.

Bourgois P. Anthropology and epidemiology on drugs: The challenges of cross-methodological and theoretical dialogue. International Journal of Drug Policy 2002; 13(4):259-69.

Bourgois P. Disciplining addictions: The bio-politics of methadone and heroin in the United States. Culture,-Medicine-and-Psychiatry 2000; 24(2):165-95.

Brehmer C, Iten PX. Medical prescription of heroin to chronic heroin addicts in Switzerland - a review. Forensic Sci Int 2001; 121(1-2):23-6.

Brissette S. Medical prescription of heroin--a review. Can HIV AIDS Policy Law Rev 2001; 6(1-2):1, 92-8.

Broers B, Perneger T, Mino A. Regarding "The Swiss heroin trials: Scientifically sound?". J Subst Abuse Treat 2000; 19(3):212-3.

Brugal MT, Barrio G, De LF, Regidor E, Royuela L, Suelves JM. Factors associated with non-fatal heroin overdose: assessing the effect of frequency and route of heroin administration. Addiction 2002; 97(3):319-27.

Buning E. Substitution programmes. Advantages and disadvantages. Maintenance or adjuvant therapy. Access to health care and social reintegration. Ann Med Interne (Paris) 1994; 145 Suppl 3:98-9.

Buning EC, Van Brussel GH, Van Santen G. The 'methadone by bus' project in Amsterdam. Br J Addict 1990; 85(10):1247-50.

Carnwath T, Merrill J. Dose equivalents in opioid substitution treatment. International Journal of Drug Policy 2002; 13(6):445-7.

Carroll KM, Ball SA, Nich C et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: Efficacy of contingency management and significant other involvement. Archives-of-General-Psychiatry 2001; 58(8):755-61.

Clark N, Lintzeris N, Gijsbers A et al. LAAM maintenance vs methadone maintenance for heroin dependence. Cochrane Database Syst Rev 2002; (2):CD002210.

Cohen P. Regarding "The Swiss heroin trials: Scientifically sound?". J Subst Abuse Treat 2000; 19(3):209-10.

Cone EJ, Preston KL. Toxicologic aspects of heroin substitution treatment. Ther Drug Monit 2002; 24(2):193-8.

Conway KP, Swendsen JD, Rounsaville BJ, Merikangas KR. Personality, drug of choice, and comorbid psychopathology among substance abusers. Drug Alcohol Depend 2002; 65(3):225-34.

Copeman M. Heroin prescription for opioid addicts. Lancet 2002; 359(9309):889-90.

Coppel A. [Substitution practices in Europe and reduction of risks]. Ann Med Interne (Paris) 1994; 145 Suppl 3:73-4.

Curran HV, Bolton J, Wanigaratne S, Smyth C. Additional methadone increases craving for heroin: a double-blind, placebo-controlled study of chronic opiate users receiving methadone substitution treatment. Addiction 1999; 94(5):665-74.

Davoli M, Ferri M, Perucci CA, Liberati A.  Health policies on drug dependence must be based on scientific evidence. BMJ 2002; 324(7349): 1338.

Dazord A, Broers B, Giner F, Mino A. Qualite de la vie de patients toxicomanes ayant une prise en charge comportant une prescription controlee d'heroiene. / Quality of life in drug abusers being managed with a controlled heroin prescription. Annales-Medico-Psychologiques 1998; 156(10):681-93.

De Ducla M, Gagnon A, Mucchielli A, Robinet S, Vellay A. Comparison of high dose buprenorphine treatments of opiate dependent outpatients in four healthcare networks. Ann Med Interne (Paris) 2000; 151 Suppl B:B9-15.

Deglon JJ. [Are maintenance substitution practices indicated in the framework of health care of drug addicts?]. Ann Med Interne (Paris) 1994; 145 Suppl 3:92-3.

Drucker E. Injectable heroin substitution treatment for opioid dependency. Lancet 2001; 358(9291):1385.

Drucker E. Regarding "The Swiss heroin trials: Scientifically sound?". J Subst Abuse Treat 2000; 19(3):211-2.

Duburcq A, Charpak Y, Blin P, Madec L. [Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex)]. Rev Epidemiol Sante Publique 2000; 48(4):363-73.

Eaton L. UK government approves heroin use on prescription. BMJ 2002; 325(7376):1321.

Edwards G. The British approach to the treatment of heroin addiction. Lancet 1969; 1(7598):768-72.

Farrell M. Methadone treatment programmes in the United Kingdom. Ann Med Interne (Paris) 1994; 145 Suppl 3:34-5.

Fhima A, Henrion R, Lowenstein W, Charpak Y. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)]. Ann Med Interne (Paris) 2001; 152 Suppl 3:IS26-36.

Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med 2002; 347(11):817-23.

Fiellin DA, O'Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med 2002; 137(8):688-92.

Fiellin DA, Pantalon MV, Pakes JP, O'Connor PG, Chawarski M, Schottenfeld RS. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002; 28(2):231-41.

Fiellin DA, Rosenheck RA, Kosten TR. Coordination of medical care and opioid dependence treatment in primary care: a case report. Subst Abus 2003; 24(1):43-6.

Fischer B, Rehm J, Kirst M et al. Heroin-assisted treatment as a response to the public health problem of opiate dependence. Eur J Public Health 2002; 12(3):228-34.

Franques P, Auriacombe M, Piquemal E et al. Sensation seeking as a common factor in opioid dependent subjects and high risk sport practicing subjects. A cross sectional study. Drug Alcohol Depend 2003; 69(2):121-6.

Gerra G, Zaimovic A, Raggi MA et al. Aggressive responding of male heroin addicts under methadone treatment: psychometric and neuroendocrine correlates. Drug Alcohol Depend 2001; 65(1):85-95.

Gogineni A, Stein MD, Friedmann PD. Social relationships and intravenous drug use among methadone maintenance patients. Drug Alcohol Depend 2001; 64(1):47-53.

Gonzalez G, Oliveto A, Kosten TR. Treatment of heroin (diamorphine) addiction: current approaches and future prospects. Drugs 2002; 62(9):1331-43.

Gschwend P, Rehm J, Lezzi S et al. Development of a monitoring system for heroin-assisted substitution treatment in Switzerland. Soz Praventivmed 2002; 47(1):33-8.

Haro G, Martinez-Raga J, Castellano M, Bolinches F, de Vicente P, Valderrama JC. [Heroin prescribing: Is there scientific evidence of its efficacy for the treatment of its dependence?]. Actas Esp Psiquiatr 2001; 29(5):343-8.

Hartnoll R. Regarding "The Swiss heroin trials: Scientifically sound?". J Subst Abuse Treat 2000; 19(3):210-1.

Hopfer CJ, Khuri E, Crowley TJ, Hooks S. Adolescent heroin use: a review of the descriptive and treatment literature. J Subst Abuse Treat 2002; 23(3):231-37.

Iruin A, Aizpurua I, Ruiz de Apodaka J, Zapirain E, Aizpuru A. [Review of scientific evidence on alternatives to methadone in the psychopharmacologic treatment of opiate dependence]. Rev Esp Salud Publica 2001; 75(3):207-19.

Killias M, Rabasa J. Does heroin prescription reduce crime? Results from the evaluation of the Swiss heroin prescription projects. Studies on Crime and Crime Prevention 1998; 7(1):127-33.

Killias M, Uchtenhagen A. Does medical heroin prescription reduce delinquency among drug-addicts? On the evaluation of the Swiss heroin prescription projects and its methodology. Studies on Crime and Crime Prevention 1996; 5(2):245-56.

Killias MAMF, Ribeaud D. Learning through controlled experiments: Community service and heroin prescription in Switzerland. Crime-and-Delinquency 2000; 46(2):233-51.

Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2002; (2):CD001333.

Kirchmayer U, Davoli M, Verster AD, Amato L, Ferri A, Perucci CA. A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction 2002; 97(10):1241-9.

Klingemann H. National treatment systems in global perspective. Eur Addict Res 1999; 5(3):109-17.

Kuo I, Brady J, Butler C et al. Feasibility of referring drug users from a needle exchange program into an addiction treatment program: Experience with a mobile treatment van and LAAM maintenance. J Subst Abuse Treat 2003; 24(1):67-74.

Kutz I, Reznik V. Rapid heroin detoxification using a single high dose of buprenorphine. J Psychoactive Drugs 2001; 33(2):191-3.

Ladewig D, Dursteler-MacFarland KM, Seifritz E, Hock C, Stohler R. New aspects in the treatment of heroin dependence with special reference to neurobiological aspects. Eur Psychiatry 2002; 17(3):163-6.

Lawrence G, Bammer G, Chapman S. 'Sending the wrong signal': analysis of print media reportage of the ACT heroin prescription trial proposal, August 1997. Aust N Z J Public Health 2000; 24(3):254-64.

Lemmens PH. Dutch government backs down on heroin prescription, despite successful trial. Addiction 2003; 98(3):247-9.

Lenne M, Lintzeris N, Breen C et al. Withdrawal from methadone maintenance treatment: prognosis and participant perspectives. Aust N Z J Public Health 2001; 25(2):121-5.

Lepere B, Gourarier L, Sanchez M et al. [Reduction in the number of lethal heroin overdoses in France since 1994. Focus on substitution treatments]. Ann Med Interne (Paris) 2001; 152 Suppl 3:IS5-12.

Levasseur L, Marzo JN, Ross N, Blatier C. [Frequency of re-incarcerations in the same detention center: role of substitution therapy. A preliminary retrospective analysis]. Ann Med Interne (Paris) 2002; 153(3 Suppl):1S14-9.

Liechti F, Falcato L, Farland KM, Rossler W, Stohler R. [Psychosocial characteristics, methadone dose and heroin use in ambulatory methadone treatment: a matched-pair design]. Soz Praventivmed 2002; 47(1):44-7.

Linehan MM, Dimeff LA, Reynolds SK et al. Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend 2002; 67(1):13-26.

Ling W, Rawson RA, Compton M. Clinical treatment of opioid addiction and dependence. Methods Mol Med 2003; 84:285-95.

Lintzeris N. Buprenorphine dosing regime in the management of out-patient heroin withdrawal. Drug Alcohol Rev 2002; 21(1):39-45.

Lintzeris N, Bell J, Bammer G, Jolley DJ, Rushworth L. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction 2002; 97(11):1395-404.

Lintzeris N, Ritter A, Dunlop A, Muhleisen P. Training primary health care professionals to provide buprenorphine and LAAM treatment. Subst Abus 2002; 23(4):245-54.

Lipsedge MS, Cook CC. Prescribing for drug-addicts. Lancet 1987; 1(8544):1265.

Lowenstein W, Haas C, Durand H. [Do substitution treatments reduce the incidence of human immunodeficiency virus infections in intravenous heroin addicts? Review of pertinent literature]. Ann Med Interne (Paris) 1994; 145 Suppl 3:75-8.

Marks JA. The prescribing debate (continued). Br J Psychiatry 1990; 157:460.

Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double- blind trial with 405 opioid-dependent patients. Addiction 2003; 98(4):441-52.

Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2002; (4):CD002209.

Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2002; (4):CD002207.

McCusker C, Davies M. Prescribing drug of choice to illicit heroin users: the experience of a U.K. community drug team. J Subst Abuse Treat 1996; 13(6):521-31.

McMahon TJ, Winkel JD, Suchman NE, Luthar SS. Drug dependence, parenting responsibilities, and treatment history: why doesn't mom go for help? Drug Alcohol Depend 2002; 65(2):105-14.

Metrebian N, Carnwath T, Stimson GV, Storz T.  Survey of doctors prescribing diamorphine (heroin) to opiate-dependent drug users in the United Kingdom. Addiction 2002; 97(9):1155-61.

Mintzer MZ, Stitzer ML. Cognitive impairment in methadone maintenance patients. Drug Alcohol Depend 2002; 67(1):41-51.

Moryl N, Santiago Palma J, Kornick C et al. Pitfalls of opioid rotation: Substituting another opioid for methadone in patients with cancer pain. Pain 2002; 96(3):325-8.

Okruhlica L, Kaco J, Klempova D. Sports activities in the prevention of heroin dependency. Eur Addict Res 2001; 7(2):83-6.

Orr AS, Wynia MK. Ethics and heroin prescription: no more fuzzy goals! Am J Bioeth 2002; 2( 2):52-3.

Petry NM, Bickel WK. Gender differences in hostility of opioid-dependent outpatients: Role in early treatment termination. Drug Alcohol Depend 2000; 58(1-2):27-33.

Polak F, Webster P. Regarding "The Swiss heroin trials: Scientifically sound?". J Subst Abuse Treat 2000; 19(3):209.

Pugatch D, Strong LL, Has P et al. Heroin use in adolescents and young adults admitted for drug detoxification. J Subst Abuse 2001; 13(3):337-46.

Rahim RT, Adler MW, Meissler JJ Jr et al. Abrupt or precipitated withdrawal from morphine induces immunosuppression. J Neuroimmunol 2002; 127(1-2):88-95.

Raisch DW, Fye CL, Boardman KD, Sather MR. Opioid dependence treatment, including buprenorphine/naloxone. Ann Pharmacother 2002; 36(2):312-21.

Rawson RA, Washton A, Domier CP, Reiber C. Drugs and sexual effects: role of drug type and gender. J Subst Abuse Treat 2002; 22(2):103-8.

Rehm J. The role of consumers. Reflection on the possibilities and limits of user interviews in opiate addiction treatment. Subst Use Misuse 2002; 37(4):533-6.

Reisinger M. [Report on the buprenorphine substitution experience in urban medicine in Belgium]. Ann Med Interne (Paris) 1994; 145 Suppl 3:46-7.

Roozen HG, Kerkhof AJ, Van Den Brink W. Experiences with an outpatient relapse program (community reinforcement approach) combined with naltrexone in the treatment of opioid- dependence: effect on addictive behaviors and the predictive value of psychiatric comorbidity. Eur Addict Res 2003; 9(2):53-8.

Sanchez-Carbonell X, Vilaregut A. A 10-year follow-up study on the health status of heroin addicts based on official registers. Addiction 2001; 96(12):1777-86.

Satel SL, Aeschbach E. The Swiss heroin trials. Scientifically sound? J Subst Abuse Treat 1999; 17(4):331-5.

Schroeder JR, Latkin CA, Hoover DR, Curry AD, Knowlton AR, Celentano DD. Illicit drug use in one's social network and in one's neighborhood predicts individual heroin and cocaine use. Ann Epidemiol 2001; 11 (6):389-94.

Seifert J, Metzner C, Paetzold W et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone. Pharmacopsychiatry 2002; 35(5):159-64.

Sheldon T. Dutch report advises prescribing heroin for misusers. BMJ 1995; 310(6995):1625.

Sheldon T. Netherlands considers prescribing heroin to addicts. BMJ 2002; 324(7334):385.

Spruit IP. The effectiveness of the medical prescription of heroin studied by randomized trials in The Netherlands, watched suspiciously by parliament and neighborhoods. Subst Use Misuse 2002; 37(4):555-63.

Sprumont D. Ethical evaluation of heroin-prescription research: an insider's view. Am J Bioeth 2002; 2(2):63-4.

Staton M, Leukefeld C. Heroin maintenance and the United States. Subst Use Misuse 2002; 37(4):549-54.

Steffen T, Blattler R, Gutzwiller F, Zwahlen M. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. Eur J Public Health 2001; 11(4):425-30.

Steffen T, Christen S, Blattler R, Gutzwiller F. Infectious diseases and public health: risk-taking behavior during participation in the Swiss program for a medical prescription of narcotics (PROVE). Subst Use Misuse 2001; 36(1-2):71-89.

Stevenson GW, Canadas F, Zhang X, Rice KC, Riley AL. Morphine discriminative control is mediated by the mu opioid receptor: Assessment of delta opioid substitution and antagonism. Pharmacology, Biochemistry and Behavior 2000; 66(4):851-6.

Stimmel B. Maintenance therapy for opioid addiction with methadone, LAAM and buprenorphine: the Emperor's New Clothes Phenomenon. J Addict Dis 2001; 20(4):1-5.

Stimson GV, Ogborne AC. Survey of addicts prescribed heroin at London clinics. Lancet 1970; 1(7657):1163-6.

Strang J. Looking beyond death: paying attention to other important consequences of heroin overdose. Addiction 2002; 97(8):927-8.

Thirion X, Lapierre V, Micallef J et al. Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend 2002; 65(2):197-204.

Umbricht A, Hoover DR, Tucker MJ, Leslie JM, Chaisson RE, Preston KL. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug Alcohol Depend 2003; 69(3):263-72.

Van Kolfschooten F. Dutch investigators recommend prescription of heroin to addicts. Lancet 2002; 359(9306):590.

Varescon I, Vidal-Trecan G, Nabet N, Boissonnas A. [Buprenorphine abuse: high dose intravenous administration of buprenorphine]. Encephale 2002; 28(5 Pt 1):397-402.

Vignau J, Brunelle E. Differences between general practitioner- and addiction centre- prescribed buprenorphine substitution therapy in France. Preliminary results. Eur Addict Res 1998; 4 Suppl 1:24-8.

Wodak A. Methadone and heroin prescription: babies and bath water. Subst Use Misuse 2002; 37(4):523-31.

Wodak AD, Ritter AJ, Watson CR. Separating politics and scientific research on heroin prescription. Med J Aust 2002; 176(9):449; author reply 450.

Yeomans MR, Gray RW. Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev 2002; 26(6):713-28.

Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 2003; 69(3):215-32.

Zinkernagel C, Naef MR, Bucher HC, Ladewig D, Gyr N, Battegay M. Onset and pattern of substance use in intravenous drug users of an opiate maintenance program. Drug Alcohol Depend 2001; 64(1):105-9.

Zunzunegui MV. [Is the medical prescription of heroin a treatment option for heroin addiction? The PEPSA Team (The Experimental Program of Narcotic Prescription in Andalucia]. Med Clin (Barc) 1999; 113(6):219-21.